ImmunoChem Therapeutics, LLC

Blocking neuroinflammation to stop cognitive decline

Victor Shifrin, CEO | vshifrin@ic-rx.com | 617-872-0639

ImmunoChem is a clinical-stage virtual start-up developing brain-penetrant small molecule NCEs for **neuroinflammation**, which is a major cause of memory loss and cognitive decline in Alzheimer's disease, brain injury, and stroke. Our leading clinical asset, **MW189**, is in an NIH-funded Phase 2a trial in hemorrhagic stroke.

MARKET & COMMERCIALIZATION STRATEGY

Go-to-Market indication: **Hemorrhagic stroke**. Label expansion: **Alzheimer's disease,** epilepsy, TBI.

Hemorrhagic stroke (103K cases/year) is a neuroinflammation-driven condition lacking any disease-modifying drugs. We plan to Fast-Track MW189's development as an Orphan Drug by targeting a rare form of hemorrhagic stroke as an initial indication, and then using it as a beachhead market for expanding into Alzheimer's disease and/or other neurodegenerative conditions.

Alzheimer's disease affects more than 6.7M Americans (1 in 9 people age 65 and older), and none of the marketed drugs can slow their cognitive decline. Neuroinflammation is one of the major druggable targets for Alzheimer's disease.

TECHNICAL & COMPETITIVE ADVANTAGE

MW189 has several advantages over other anti-neuroinflammatory drugs that are in clinical trials for Alzheimer's disease:

- → Excellent safety profile, no immunosuppression;
- → Oral bioavailability and rapid CNS penetrance;
- → Chemical and metabolic stability;
- → De-risked in a Phase 1b trial: endotoxin challenge in healthy volunteers;
- → **Low manufacturing costs;**
- → **Protection from "me-too drug" competition.**



REGULATORY STRATEGY & INTELLECTUAL PROPERTY

Open Phase 2 IND; full term follow-on patents with current priority dates are under development.

KEY CLINICAL MILESTONES

- **Phase 2a First-in-Patient trial in hemorrhagic stroke (Proof-of-Concept)** — **Ongoing, ends in 2026**
- Phase 2b trial in a Go-to-Market Orphan Disease indication — Planned, 2027

CAPITALIZATION HISTORY

Four non-dilutive, peer-reviewed Fast Track SBIR grants from the NIH (NIA, NCI, NINDS) during the last 5 years.

MANAGEMENT TEAM / FOUNDERS

Victor Shifrin, PhD, CEO; Previously of Eisai USA, CombinatoRx, Biogen; 20+ years of R&D/clinical development/management in oncology and inflammation.

Manfred Windisch, PhD, VP of Regulatory Affairs; 30+ years in clinical research; 44 clinical trials in Alzheimer's disease and stroke.

Linda Van Eldik, PhD, Head of Research & Clinical Development, Scientific Founder and one of the inventors of MW189; Director, U of KY Alzheimer's Disease Research Center; 25+ years in Alzheimer's disease research; an internationally recognized expert on neuroinflammation.

NEXT STEP

Advance MW189's clinical development into a Phase 2b trial in an Orphan Disease indication for accelerated NDA / marketing authorization approvals.